IDSA: Earlier introduction of HPV vaccine improves initiation, completion by age 13
Introducing the human papillomavirus (HPV) vaccine at ages 9 to 10 years rather than 11 to 12 years leads to a meaningful difference in initiation and completion of the vaccine series, including initiation and completion by age 13 years, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 21 to 24 in Washington, D.C.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
